A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

NCT01514461 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Familial Chylomicronemia Syndrome (FCS)

Interventions

DRUG: LCQ908
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals